The promising results of a phase 1 immunotherapy trial marks the first major advance in the treatment of advanced bladder cancer for 30 years. (Courtesy of Medical News Today)
The promising results of a phase 1 immunotherapy trial marks the first major advance in the treatment of advanced bladder cancer for 30 years. (Courtesy of Medical News Today)
The promising results of a phase 1 immunotherapy trial marks the first major advance in the treatment of advanced bladder cancer for 30 years. (Courtesy of Medical News Today)

(Medical News Today) – The result marks the first major advance in the treatment of advanced bladder cancer for 30 years, note the researchers, who report their findings in the journal Nature.

Lead author Dr. Tom Powles, consultant medical oncologist at Barts Cancer Institute, Queen Mary University of London in the UK, says:

“This study is a hugely exciting step forward in the search for alternative advanced bladder cancer treatment. For decades chemotherapy has been the only option, with a poor outcome and many patients too ill to cope with it.”

He and his colleagues conducted a trial of Roche’s experimental cancer immunotherapy drug MPDL3280A – an antibody that blocks PD-L1 – a protein that is believed to help cancer cells evade immune detection.

READ MORE

Leave a comment

Your email address will not be published.

Yes, I would like to receive emails from Washington Informer Newspaper. Sign me up!


By submitting this form, you are consenting to receive marketing emails from: Washington Informer Newspaper, 3117 Martin Luther King Jr. Ave SE, Washington, DC, 20032, https://www.washingtoninformer.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact